PE20160877A1 - Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion - Google Patents
Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacionInfo
- Publication number
- PE20160877A1 PE20160877A1 PE2016000398A PE2016000398A PE20160877A1 PE 20160877 A1 PE20160877 A1 PE 20160877A1 PE 2016000398 A PE2016000398 A PE 2016000398A PE 2016000398 A PE2016000398 A PE 2016000398A PE 20160877 A1 PE20160877 A1 PE 20160877A1
- Authority
- PE
- Peru
- Prior art keywords
- amino acids
- sequence
- heterogenic
- populations
- recombinant human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Water Supply & Treatment (AREA)
- Toxicology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881834P | 2013-09-24 | 2013-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160877A1 true PE20160877A1 (es) | 2016-09-11 |
Family
ID=51844797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000398A PE20160877A1 (es) | 2013-09-24 | 2014-09-16 | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9757434B2 (OSRAM) |
| EP (1) | EP3049434A1 (OSRAM) |
| JP (1) | JP6429885B2 (OSRAM) |
| KR (1) | KR101988705B1 (OSRAM) |
| CN (2) | CN105579468A (OSRAM) |
| AR (1) | AR097732A1 (OSRAM) |
| AU (1) | AU2014326257B2 (OSRAM) |
| BR (1) | BR112016005899A8 (OSRAM) |
| CA (1) | CA2924981C (OSRAM) |
| HK (1) | HK1218760A1 (OSRAM) |
| IL (2) | IL244258A0 (OSRAM) |
| MX (1) | MX373466B (OSRAM) |
| MY (1) | MY173548A (OSRAM) |
| PE (1) | PE20160877A1 (OSRAM) |
| RU (1) | RU2648144C2 (OSRAM) |
| SA (1) | SA516370751B1 (OSRAM) |
| SG (1) | SG11201601221XA (OSRAM) |
| TW (1) | TWI631134B (OSRAM) |
| WO (1) | WO2015044836A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150343034A1 (en) | 2013-01-31 | 2015-12-03 | Pfizer Inc. | Compositions and methods for counteracting factor xa inhibition |
| CN105579468A (zh) | 2013-09-24 | 2016-05-11 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
| ES2875538T3 (es) | 2016-06-17 | 2021-11-10 | Alexion Pharma Inc | Preparación de derivados del factor Xa |
| EP3722418A1 (en) * | 2019-04-08 | 2020-10-14 | AB Enzymes Oy | Solution stable enzyme composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| AU2001249389A1 (en) | 2000-03-22 | 2001-10-03 | The Children's Hospital Of Philadelphia | Modified blood clotting factors and methods of use |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| DK1781782T3 (da) | 2004-08-17 | 2010-08-23 | Csl Behring Gmbh | Modificerede vitamin K-afhængige polypeptider |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| MX336958B (es) * | 2005-11-15 | 2016-02-05 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| KR102069498B1 (ko) * | 2007-09-28 | 2020-01-23 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법 |
| PL2300497T3 (pl) | 2008-06-24 | 2013-02-28 | Octapharma Ag | Sposób oczyszczania czynnika krzepnięcia VIII |
| US8455439B2 (en) | 2008-11-14 | 2013-06-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents |
| KR20110114587A (ko) | 2008-12-19 | 2011-10-19 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도 |
| ES2605801T3 (es) | 2009-07-15 | 2017-03-16 | Portola Pharmaceuticals, Inc. | Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia |
| SI2591006T1 (sl) * | 2010-07-09 | 2019-10-30 | Bioverativ Therapeutics Inc | Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo |
| FR2972114B1 (fr) | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| EP2760887B1 (en) | 2011-09-30 | 2024-10-23 | The Children's Hospital of Philadelphia | Compositions and methods for modulating hemostasis |
| CN104755492A (zh) | 2012-07-25 | 2015-07-01 | 催化剂生物科学公司 | 修饰的因子x多肽及其应用 |
| US20150343034A1 (en) | 2013-01-31 | 2015-12-03 | Pfizer Inc. | Compositions and methods for counteracting factor xa inhibition |
| CN105579468A (zh) | 2013-09-24 | 2016-05-11 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
| WO2015066606A2 (en) | 2013-11-01 | 2015-05-07 | The Children's Hospital Of Philadelphia | Compositions and methods for increasing the half-life of factor xa |
| PT3096779T (pt) | 2014-01-24 | 2020-02-21 | Pfizer | Composições e métodos para tratamento de hemorragia intracerebral |
-
2014
- 2014-09-16 CN CN201480052212.2A patent/CN105579468A/zh active Pending
- 2014-09-16 CN CN202011112690.1A patent/CN112195169A/zh active Pending
- 2014-09-16 RU RU2016108608A patent/RU2648144C2/ru active
- 2014-09-16 AU AU2014326257A patent/AU2014326257B2/en not_active Ceased
- 2014-09-16 SG SG11201601221XA patent/SG11201601221XA/en unknown
- 2014-09-16 KR KR1020167007373A patent/KR101988705B1/ko not_active Expired - Fee Related
- 2014-09-16 CA CA2924981A patent/CA2924981C/en not_active Expired - Fee Related
- 2014-09-16 WO PCT/IB2014/064564 patent/WO2015044836A1/en not_active Ceased
- 2014-09-16 BR BR112016005899A patent/BR112016005899A8/pt not_active IP Right Cessation
- 2014-09-16 JP JP2016543477A patent/JP6429885B2/ja not_active Expired - Fee Related
- 2014-09-16 EP EP14792595.2A patent/EP3049434A1/en not_active Withdrawn
- 2014-09-16 HK HK16106674.2A patent/HK1218760A1/zh unknown
- 2014-09-16 MX MX2016003871A patent/MX373466B/es active IP Right Grant
- 2014-09-16 PE PE2016000398A patent/PE20160877A1/es unknown
- 2014-09-16 MY MYPI2016700985A patent/MY173548A/en unknown
- 2014-09-23 AR ARP140103512A patent/AR097732A1/es unknown
- 2014-09-23 TW TW103132803A patent/TWI631134B/zh not_active IP Right Cessation
- 2014-09-24 US US14/495,478 patent/US9757434B2/en not_active Expired - Fee Related
-
2016
- 2016-02-23 IL IL244258A patent/IL244258A0/en unknown
- 2016-03-17 SA SA516370751A patent/SA516370751B1/ar unknown
-
2017
- 2017-08-04 US US15/669,340 patent/US10660946B2/en active Active
-
2020
- 2020-05-25 US US16/882,598 patent/US20210106658A1/en not_active Abandoned
- 2020-12-13 IL IL279396A patent/IL279396A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY173548A (en) | 2020-02-04 |
| HK1218760A1 (zh) | 2017-03-10 |
| IL244258A0 (en) | 2016-04-21 |
| US9757434B2 (en) | 2017-09-12 |
| US20210106658A1 (en) | 2021-04-15 |
| AU2014326257B2 (en) | 2017-08-10 |
| CN112195169A (zh) | 2021-01-08 |
| US10660946B2 (en) | 2020-05-26 |
| KR20160044034A (ko) | 2016-04-22 |
| IL279396A (en) | 2021-01-31 |
| BR112016005899A2 (pt) | 2017-09-26 |
| CN105579468A (zh) | 2016-05-11 |
| TW201524996A (zh) | 2015-07-01 |
| MX373466B (es) | 2020-05-25 |
| BR112016005899A8 (pt) | 2018-02-06 |
| TWI631134B (zh) | 2018-08-01 |
| CA2924981A1 (en) | 2015-04-02 |
| US20150182604A1 (en) | 2015-07-02 |
| AR097732A1 (es) | 2016-04-13 |
| AU2014326257A1 (en) | 2016-03-10 |
| SA516370751B1 (ar) | 2018-04-05 |
| MX2016003871A (es) | 2016-08-04 |
| KR101988705B1 (ko) | 2019-06-12 |
| EP3049434A1 (en) | 2016-08-03 |
| JP6429885B2 (ja) | 2018-11-28 |
| RU2648144C2 (ru) | 2018-03-22 |
| SG11201601221XA (en) | 2016-04-28 |
| WO2015044836A1 (en) | 2015-04-02 |
| RU2016108608A (ru) | 2017-10-26 |
| US20170333535A1 (en) | 2017-11-23 |
| JP2016535071A (ja) | 2016-11-10 |
| CA2924981C (en) | 2020-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
| CL2011003003A1 (es) | Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. | |
| PE20140982A1 (es) | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta | |
| CO7051009A2 (es) | Composiciones del factor viii y métodos para hacerlas y usarlas | |
| SV2018005714A (es) | Composiciones y metodos para disminuir la expresion de tau | |
| CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| PE20180128A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| GT201700224A (es) | Proteína de unión a rgma y su uso | |
| PE20200894A1 (es) | Polipeptidos variantes del factor de crecimiento tipo insulina 1 | |
| MX2019001633A (es) | Proteina derivada de la seda para el tratamiento de la inflamacion. | |
| CY1118856T1 (el) | Εμβολιο pcsk9 | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| BR112017014580A8 (pt) | Método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína | |
| PE20160877A1 (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion | |
| AR094835A1 (es) | Péptidos bioactivos cortos que promueven la cicatrización de las heridas | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| AR092736A1 (es) | Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r | |
| PL3648788T3 (pl) | Leczenie krwawienia z przewodu pokarmowego u pacjentów z ciężką chorobą von willebranda poprzez podanie rekombinowanego vwf | |
| PE20160847A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa |